retatrutide phase 2 nejm 2023 weight loss percent 48 weeks 🚨 Today, retatrutide, the GIP/GLP-1/glucagon triple agonist, just delivered TRIUMPH-2 top-line results. A study in those with concurrent obesity and type diabetes. 📊 Mean body change at 80 weeks: ⬇️ Peptide Series #3 — Retatrutide

But if its been more than 5 days since your missed dose, skip the missed dose and go back to your regular dosing schedule

Can I choose which pharmacy my medication comes from

They are also the number one reason people botch the tirzepatide to retatrutide transition

Patients experiencing persistent skin dryness, unusual texture changes, or delayed wound healing should discuss nutritional assessment with their healthcare provider, though a direct causal relationship between GLP-1 therapy and specific nutritional deficiencies has not been firmly established

Understanding this helps set realistic expectations about when results are likely to emerge

These are not rare edge cases